
Facts & Figures

IN BELGIUM - 05/2022




GENERIC MEDICINES IN BELGIUM IN A NUTSHELL



Source: IQVIA LMPB 03/2022 & BHA 02/2022, reimbursed medicines



2 Facts & Figures - GENERIC MEDICINES IN BELGIUM - 05/2022





GENERIC MEDICINES IN BELGIUM: LIMITED USE (2021)

IN PUBLIC PHARMACIES	#Molecules	Turnover (mio €)	Market share Turnover (%)	Volume (mio SU)	Market share Volume (%)
Originator medicines	719	1.912,9	82,5	4.505	58,7
Generic medicines	247	404,6	17,5	3.164	41,3
TOTAL	966	2.317,5	100	7.669	100

Generic medicines and copies

Source: IQVIA LMPB 03/2022 year 2021, reimbursed medicines, ex-factory prices



GENERIC MEDICINES IN BELGIUM: LIMITED USE (2021)


HOSPITAL IN HOSPITALS	#Molecules	Turnover (mio €)	Market share Turnover (%)	Volume (mio SU)	Market share Volume (%)
Originator medicines	1.045	3.163,4	95,5	400	84,2
Generic medicines	305	147,4	4,5	75	(15,8)
TOTAL	1.350	3.310,8	100	475	100

Generic medicines and copies

Source: IQVIA BHA 02/2022 year 2021, reimbursed medicines, ex-factory prices




GENERIC MEDICINES: BELGIUM IS LAGGING BEHIND



6 Facts & Figures - GENERIC MEDICINES IN BELGIUM - 05/2022



GENERIC MEDICINE PRICES⁽¹⁾ ARE DECREASING, WHEREAS NEW MEDICINE PRICES⁽²⁾ ARE INCREASING⁽³⁾



As IQVIA figures are used, the cost price of medicines is expressed as ex-factory price (expressed per unit) (coded as SU in the IQVIA database).

(3) Market of reimbursed medicines, distributed via public pharmacies.




Source: IQVIA LMPB 02/2022

7 Facts & Figures - GENERIC MEDICINES IN BELGIUM - 05/2022


⁽²⁾ New medicine means: a medicine that has not vet been reimbursed for 12 years and for which no generic or biosimilar version is (vet) available on the market (01/09/2021). Capping at the age of 12 is done since medicines under 12 years of age are not subject reductions linked to the 'age' of the medicine, often followed by additional price decreases due to annual budget saving measures). Such 'age-related' price decreases are applied as a matter of law to medicines that have been reimbursed for 12 years or more. Moreover. both originator and generic medicines are subject to these legal price reductions. This graph could not take 'managed entry agreements' or 'article 81/articles 111-112-113 agreements', as these benefit from a legally protected confidentiality.

GENERIC MEDICINES: PRICE EROSION



Source: IQVIA LMPB 02/2022






Sources: - IQVIA: LMPB 02/2022 (ex-factory price per SU in €, weighted average Medaxes generic medicines and copies)

- Statbel: https://statbel.fgov.be/en/themes/consumer-prices/consumer-price-index#figures (December indices, reference year 2004 = 100) (01/05/2022)

- Eurostat: https://ec.europa.eu/eurostat/databrowser/view/STS_INPPD_A_custom_2111482/default/table?lang=en (Annual indices, reference year 2015 = 100) (20/05/2022)

GENERIC MEDICINES: SMALL OPERATING BASE IN PUBLIC PHARMACIES



nearly

72% of generic medicines in public pharmacies have a turnover of less than 100 K €


• Turnover SKU Gx > 10 mio € (0,08%)

- 5 mio € < Turnover SKU Gx < 10 mio € (0,04%)
- 1 mio € < Turnover SKU Gx < 5 mio € (3,00%)
- 100 k € < Turnover SKU Gx < 1 mio € (25,17%)
- Turnover SKU Gx < 100 k € (71,72%)

Source: IQVIA LMPB 03/2022 year 2021, reimbursed medicines, ex-factory prices



GENERIC MEDICINES: SMALL OPERATING BASE IN HOSPITALS



more than 88% of generic medicines in hospitals have a turnover of less than 100 K €

- Turnover SKU Gx > 10 mio € (0,06%)
- 5 mio € < Turnover SKU Gx < 10 mio € (0,18%)
- 1 mio € < Turnover SKU Gx < 5 mio € (1,59%)
- 100 k € < Turnover SKU Gx < 1 mio € (10,08%)
- Turnover SKU Gx < 100 k € (88,09%)

Source: IQVIA BHA 02/2022 year 2021, reimbursed medicines, ex-factory prices



1 generic medicine* per day disappeared from the market over the past 2 years

*SKU

793 reimbursed generic medicines either definitely disappeared from the market

Source: figures based on Medaxes's cross analyses of data from FAMHP PharmaStatus, NIHDI and IQVIA

or were not available for more than 12 months between February 2020 and January 2022.

> Medaxes Association for accessible medicines

12 Facts & Figures - GENERIC MEDICINES IN BELGIUM - 05/2022

XXXXXXX

XXXXXXX

XXXXXXX

ABOUT MEDAXES

Our mission

Medaxes is the Belgian association of pharmaceutical companies that want to contribute to making healthcare accessible to all.

Medaxes focuses on generic and biosimilar medicines, as well as on other off-patent medicines and self-care products.

Medaxes aims to provide high quality solutions for efficient and sustainable healthcare in a well-regulated environment.

Medaxes strives to build a dialogue and work in partnership with other healthcare stakeholders. For its members, Medaxes acts as a representative platform, offering a wide range of services in support of their individual activities and common interests.





Medaxes vzw/asbl Sint-Amandsstraat 2 - 1853 Strombeek-Bever - T +32 (0)3 820 14 88 www.medaxes.be - info@medaxes.be Responsible publisher: Joris Van Assche

